SEC Form SC 13G/A filed by Entrada Therapeutics Inc. (Amendment)

$TRDA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $TRDA alert in real time by email
SC 13G/A 1 tm245948d1_sc13ga.htm SC 13G/A

CUSIP No. 29384C108

SCHEDULE 13G Page 1 of 7

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_________________

 

SCHEDULE 13G

_________________

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)*

 

Entrada Therapeutics, Inc.
(Name of Issuer)
 
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
 
29384C108
(CUSIP Number)
 
December 31, 2023
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

 

¨Rule 13d-1(c)

 

xRule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

  

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 29384C108

SCHEDULE 13GPage 2 of 7

 

1. NAMES OF REPORTING PERSONS
Roche Finance Ltd
   
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a) ¨
  (b) ¨
3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Switzerland

NUMBER OF 5. SOLE VOTING POWER 0
SHARES    
BENEFICIALLY    
OWNED BY 6.

SHARED VOTING POWER 2,744,120

 

EACH    
REPORTING 7.

SOLE DISPOSITIVE POWER 0

 

PERSON WITH    
  8.

SHARED DISPOSITIVE POWER 2,744,120

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,744,120

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

8.2%

12.

TYPE OF REPORTING PERSON (See Instructions)

 

CO

       

 

CUSIP No. 29384C108

SCHEDULE 13GPage 3 of 7

 

 

1. NAMES OF REPORTING PERSONS
Roche Holding Ltd
   
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a) ¨
  (b) ¨
3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Switzerland

NUMBER OF 5. SOLE VOTING POWER 0
SHARES    
BENEFICIALLY    
OWNED BY 6.

SHARED VOTING POWER 2,744,120

 

EACH    
REPORTING 7.

SOLE DISPOSITIVE POWER 0

 

PERSON WITH    
  8.

SHARED DISPOSITIVE POWER 2,744,120

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,744,120

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

8.2%

12.

TYPE OF REPORTING PERSON (See Instructions)

 

CO

       

 

 

CUSIP No. 29384C108

SCHEDULE 13GPage 4 of 7

 

 

Item 1(a).Name of Issuer:

 

Entrada Therapeutics, Inc., a Delaware corporation (the “Issuer”).

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

6 Tide Street, Boston, Massachusetts 02210

 

Item 2.

 

(a) Name of Person Filing: Roche Finance Ltd and Roche Holding Ltd

 

(b) Address or principal business office or, if none, residence:

 

Roche Finance Ltd: Grenzacherstrasse 122, 4070 Basel, Switzerland.

 

Roche Holding Ltd: Grenzacherstrasse 124, 4070 Basel, Switzerland.

 

(c) Citizenship:

 

Roche Finance Ltd: Switzerland

 

Roche Holding Ltd: Switzerland

 

(d) Title of Class of Securities: Common Stock, $0.0001 par value per share.

 

(e) CUSIP No.: 29384C108.

 

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

Item 4.Ownership:

 

(a)Each of the Reporting Persons may be deemed to beneficially own 2,744,120 shares of Common Stock.*

 

(b)Percent of Class: Each Reporting Person may be deemed to beneficially own 8.2%, based on 33,368,078 shares of Common Stock outstanding as of November 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2023.*

 

(c)Number of shares as to which each Reporting Person has:

 

(i)Sole power to vote or to direct the vote: 0.

 

(ii)Shared power to vote or to direct the vote: 2,744,120.

 

(iii)Sole power to dispose or to direct the disposition of: 0.

 

(iv)Shared power to dispose or to direct the disposition of: 2,744,120.

 

*Roche Holding Ltd may be deemed to have beneficial ownership of the 2,744,120 shares directly beneficially owned by Roche Finance Ltd, its wholly-owned subsidiary.

 

 

CUSIP No. 29384C108

SCHEDULE 13GPage 5 of 7

 

 

Item 5.Ownership of Five Percent or Less of a Class:

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

 

Not applicable.

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person:

 

Not applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

 

Roche Finance Ltd is a wholly-owned subsidiary of Roche Holding Ltd.

 

Item 8.Identification and Classification of Members of the Group:

 

Not applicable.

 

Item 9.Notice of Dissolution of Group:

 

Not applicable.

 

Item 10.Certification:

 

Not applicable.

 

 

CUSIP No. 29384C108

SCHEDULE 13GPage 6 of 7

 

 

SIGNATURE

 

After reasonable inquiry and to the best of their knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated this 14th day of February, 2024

 

  ROCHE FINANCE LTD 
       
       
  By:  /s/ Carole Nuechterlein 
  Carole Nuechterlein, Authorized Signatory 
       
       
  By:  /s/ Peter Trybus 
  Peter Trybus, Authorized Signatory 
       
       
  ROCHE HOLDING LTD 
    
       
  By:  /s/ Peter Trybus 
  Peter Trybus, Authorized Signatory 
       
       
  By:  /s/ Claudia Boeckstiegel 
  Claudia Boeckstiegel, Authorized Signatory 

 

 

 

CUSIP No. 29384C108

SCHEDULE 13GPage 7 of 7

 

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13G and any future amendments thereto reporting each of the undersigned’s ownership of securities of the Issuer named herein, and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that he or it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Exchange Act, nor is a joint venture for purposes of the Investment Company Act of 1940.

 

Dated this 14th day of February, 2024

 

  ROCHE FINANCE LTD 
       
       
  By:  /s/ Carole Nuechterlein 
  Carole Nuechterlein, Authorized Signatory 
       
       
  By:  /s/ Peter Trybus 
  Peter Trybus, Authorized Signatory 
       
       
  ROCHE HOLDING LTD 
    
       
  By:  /s/ Peter Trybus 
  Peter Trybus, Authorized Signatory 
       
       
  By:  /s/ Claudia Boeckstiegel 
  Claudia Boeckstiegel, Authorized Signatory 

 

 

Get the next $TRDA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TRDA

DatePrice TargetRatingAnalyst
12/6/2024$29.00Buy
ROTH MKM
1/5/2024$22.00Outperform
Oppenheimer
4/3/2023$25.00Buy
H.C. Wainwright
11/24/2021Outperform
Evercore ISI Group
11/23/2021Outperform
Cowen & Co.
11/23/2021$29.00Neutral
Goldman Sachs
More analyst ratings

$TRDA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

    – Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent business updates. "We are thrilled to begin 2025 with significant mome

    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

    – Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initi

    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

    – Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mu

    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TRDA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TRDA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TRDA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TRDA
SEC Filings

See more

$TRDA
Leadership Updates

Live Leadership Updates

See more
  • āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

    āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

    BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit

    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Entrada Therapeutics Reports First Quarter 2023 Financial Results

    - $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates. "In the first quarter, we successfully closed on our transformational collaboration with Vertex for the development of EEV-therapeutics targeting myotonic dystrophy type 1, the most prev

    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TRDA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more